Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

EXEL 10.15.2024

Full Press ReleaseSEC FilingsOur EXEL Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.12.2025 - Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
  • 01.09.2025 - Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report

– Conference Call and Webcast to Follow at5:00 p.m. ET/2:00 p.m. PT–

ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 15, 2024--Exelixis, Inc.(Nasdaq: EXEL) announced today that its third quarter 2024 financial results will be released onTuesday, October 29, 2024after the markets close. At5:00 p.m. ET/2:00 p.m. PT,Exelixismanagement will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.

To access the conference call, please register using thislink. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log ontowww.exelixis.comand proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will also be archived onwww.exelixis.comfor one year.

AboutExelixis

Exelixisis a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib).Exelixisis driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visitwww.exelixis.com, follow@ExelixisIncon X (Twitter), likeExelixis, Inc.on Facebook and followExelixison LinkedIn.

Exelixis, theExelixislogo and CABOMETYX are registeredU.S.trademarks.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241015906059/en/

Investors Contact:Varant ShirvanianDirector, Investor RelationsExelixis, Inc.650-837-7917vshirvanian@exelixis.com

Media Contact:Hal MackinsForExelixis, Inc.415-994-0040hal@torchcommunications.com

Source:Exelixis, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com